Publications by authors named "Kevin Dale Courtney"
Article Synopsis
- Lurbinectedin is FDA-approved for treating metastatic small cell lung cancer (SCLC), but there is no data on its use for small cell or neuroendocrine prostate cancer (SC/NEPC), which behaves similarly.
- A study involving 18 SC/NEPC patients treated with lurbinectedin reported a clinical benefit rate of 56%, with common treatment-related adverse events including fatigue and anemia.
- Results showed modest clinical benefits: median overall survival was about 6 months and progression-free survival was around 3.35 months, highlighting the need for further studies to confirm lurbinectedin's effectiveness as a treatment option for SC/NEPC.
Purpose: Germline genetic testing (GT) is recommended for men with prostate cancer (PC), but testing through traditional models is limited. The ProGen study examined a novel model aimed at providing access to GT while promoting education and informed consent.
Methods: Men with potentially lethal PC (metastatic, localized with a Gleason score of ≥8, persistent prostate-specific antigen after local therapy), diagnosis age ≤55 years, previous malignancy, and family history suggestive of a pathogenic variant (PV) and/or at oncologist's discretion were randomly assigned 3:1 to video education (VE) or in-person genetic counseling (GC).